FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsor would need “no pain” result at two hours, but could use patient-identified symptom as co-primary endpoint.